ArticleMolecules (Basel, Switzerland)2021
Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent Advances in Urinary Peptide and Proteomic Biomarkers in Chronic Kidney Disease: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial.Heart (British Cardiac Society) · 2024Trial
- Urinary collagen type I degradation products as common fibrosis biomarkers in chronic diseases.Molecular medicine (Cambridge, Mass.) · 2026Article
- Peptidomic Profiling Reveals Extracellular Matrix Remodeling Signatures Discriminative of Multiple Myeloma.Proteomics · 2026Article
- Prospective validation of a urine-based proteomics test for predicting clinically significant prostate cancer in biopsy-naïve patients.British journal of cancer · 2026Article
- Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial.EBioMedicine · 2026Article
- Urinary Collagen Peptides Predict Mortality.Proteomics · 2026Article
- Clinical peptidomics for respiratory diseases: matrices, workflows, and translation towards treatable traits, with a focus on COPD.Clinical proteomics · 2026Review
- Reduced collagen degradation in pelvic urine precedes kidney fibrosis induced by unilateral ureteral obstruction.Scientific reports · 2025Article
- Article
- Investigation of the Urinary Peptidome to Unravel Collagen Degradation in Health and Kidney Disease.Proteomics · 2025Article
- Urinary Proteomics and Systems Biology Link Eight Proteins to the Higher Risk of Hypertension and Related Complications in Blacks Versus Whites.Proteomics · 2025Article
- Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney disease.Clinical kidney journal · 2025Article
- Emerging technologies for early risk stratification and precision management of diabetic kidney disease: a multimodal framework integrating digital phenotypes and clinical biomarkers.Frontiers in endocrinology · 2025Review
- Mortality Risk and Urinary Proteome Changes in Acute COVID-19 Survivors in the Multinational CRIT-COV-U Study.Biomedicines · 2024Article
- Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients.Heliyon · 2024Article
- Comparison of clean catch and bag urine using LC-MS/MS proteomics in infants.Pediatric nephrology (Berlin, Germany) · 2024Article
- Association of Air Pollution with a Urinary Biomarker of Biological Aging and Effect Modification by Vitamin K in the FLEMENGHO Prospective Population Study.Environmental health perspectives · 2023Article
- Urinary peptides provide information about the risk of mortality across a spectrum of diseases and scenarios.Journal of translational medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In recent years, capillary electrophoresis coupled to mass spectrometry (CE-MS) has been increasingly applied in clinical research especially in the context of chronic and age-associated diseases, such as chronic kidney disease, heart failure and cancer. Biomarkers identified using this technique are already used for diagnosis, prognosis and monitoring of these complex diseases, as well as patient stratification in clinical trials. CE-MS allows for a comprehensive assessment of small molecular weight proteins and peptides (<20 kDa) through the combination of the high resolution and reproducibility of CE and the distinct sensitivity of MS, in a high-throughput system. In this study we assessed CE-MS analytical performance with regards to its inter- and intra-day reproducibility, variability and efficiency in peptide detection, along with a characterization of the urinary peptidome content. To this end, CE-MS performance was evaluated based on 72 measurements of a standard urine sample (60 for inter- and 12 for intra-day assessment) analyzed during the second quarter of 2021. Analysis was performed per run, per peptide, as well as at the level of biomarker panels. The obtained datasets showed high correlation between the different runs, low variation of the ten highest average individual log2 signal intensities (coefficient of variation, CV < 10%) and very low variation of biomarker panels applied (CV close to 1%). The findings of the study support the analytical performance of CE-MS, underlining its value for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.